Introduction: Diffuse large B cell lymphoma (DLBCL), the most common lymphoma diagnosis, has heterogeneous biology and prognosis. Frontline R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), used regardless of subtype, cures ∼60%, but relapsed/refractory patients have persistently poor prognosis. Efforts to improve frontline and establish subtype-targeted therapy have largely failed.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with D.
Contact D., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack